Journal September 16, 2026 5 min read

Cerebrolysin: mechanism of action

Cerebrolysin is a multimodal neuropeptide preparation studied for its effects on neuroprotection, neuroplasticity and cerebral endothelial integrity. This page summarises the proposed mechanisms and the research models i

peptides-pro Editorial

Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain tissue, classified as a neurotrophic peptide agent. It is supplied as a sterile solution for laboratory and clinical research use. The evidence block for this page does not provide a sequence, molecular formula or molecular weight for the preparation, and none is asserted here; the material is described in the literature as a multimodal neuropeptide preparation rather than a single molecular entity [9].

The mechanistic work centres on neurotrophic and neuroplasticity signalling together with preservation of cerebral endothelial and blood-brain barrier integrity, the latter studied in vitro through tight-junction-related protein cargo in endothelial-derived exosomes [4].

Research Studies

Cerebrolysin and cerebral endothelial permeability in vitro

An in vitro endothelial permeability assay was used to test whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (termed Cerebro-Exos) act on dysfunctional cerebral endothelial cells. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated endothelial cells (Naïve-Exos); Cerebro-Exos were highly enriched in metabolic and tight junction related proteins relative to Naïve-Exos. In the same assay system, Cerebro-Exos had a superior effect to Naïve-Exos on restoring endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This finding is in vitro only and does not establish an effect in animals or in humans.

Cerebrolysin and reperfusion injury after extended-window thrombectomy

An ongoing multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery. The trial addresses a population in which thrombectomy performed 6 to 24 hours after onset can benefit selected patients, but in which some patients remain disabled despite successful reopening of the blocked artery; ongoing injury to brain tissue, small vessels and the blood-brain barrier is proposed as a contributor to that incomplete recovery [1]. No outcome data are reported in the evidence block.

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction grade 3), with adjunctive Cerebrolysin administered subsequently. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale score decreasing from 7 to 2, followed by complete neurological recovery [2]. This is a single case report; it does not establish efficacy.

Cerebrolysin and Wernicke's aphasia with speech-language therapy

A second case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischaemic stroke. Despite timely thrombolysis and mechanical thrombectomy she experienced significant neurological deficits, and early multidisciplinary rehabilitation was combined with a 10-day course of Cerebrolysin [3]. Post-stroke aphasia affects approximately one-third of stroke survivors and impairs communication, social participation and quality of life; speech-language therapy remains the standard of care, and agents such as Cerebrolysin have been proposed to enhance recovery through neuroprotection and neuroplasticity [3].

Cerebrolysin combined with speech therapy in nonfluent aphasia

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischaemic stroke [6]. The evidence block supplies the abstract title only, without effect estimates, so no quantitative claim is made here.

Cerebrolysin as an add-on to virtual reality neurorehabilitation

A second conference abstract reports work on virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. As with the preceding abstract, no numerical results are available in the evidence block.

Cerebrolysin and 12-month functional outcomes after endovascular thrombectomy

A third conference abstract reports 12-month functional outcomes in a propensity-matched cohort of patients receiving Cerebrolysin after endovascular thrombectomy in stroke [8]. The evidence block provides the abstract title only; no outcome values are reproduced here.

Cerebrolysin after tenecteplase and mechanical thrombectomy

A case report described very early short-course Cerebrolysin after tenecteplase and mechanical thrombectomy. The report notes that despite high recanalisation rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and that Cerebrolysin, described as a multimodal neuropeptide preparation, may attenuate ischaemia-reperfusion injury and support early neurorehabilitation [9].

Retracted preclinical work involving Cerebrolysin

Several preclinical reports involving Cerebrolysin have been retracted, including a regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], a study of timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11], and a study of neurotrophic effects in the Mecp2^308/Y transgenic model of Rett syndrome [12]. A further retraction note concerns a study of Cerebrolysin and exacerbation of neuropathic pain, blood-spinal cord barrier breakdown and cord pathology following chronic intoxication with engineered Ag, Cu or Al nanoparticles [5]. These retractions are recorded here because they bear on how the preclinical literature on this preparation should be weighed.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.